Belite Bio’s Post

Thanks to curated #RWD, we're gaining insights into cataracts, which are the leading cause of vision loss in the U.S. Learn how our recent partnership with the FDA and the American Academy of Ophthalmology led to major findings surrounding #IOL use among young patients with cataracts: https://hubs.la/Q02zhLTz0

Our Ophthalmology capabilites and expertise are second to none. if you have a spare minute, watch the below. AC #syneos #opthalmology

One of the ways to stay ahead in ophthalmology clinical research is by keeping up with the latest NEI findings. At True North, we leverage this knowledge to design more effective trials. What recent eye research excites you? Share below. #eyeinnovation #clinicalresearch #contractresearchorganization  National Eye Institute (NEI)

Saving the best for last! The final session of #ESCRSiNovation Day is underway with the Industry Leader Panel, which is discussing the vision of ophthalmology for the next 5 years. #ESCRS2024 #Ophthalmology #LeadershipPanel

🌟🔬 Coming soon live, from American Academy of Ophthalmology 2024! Join Dr. Austin Pereira as he delves into groundbreaking insights from Dr. Quan Dong Nguyen’s presentation on the Neptune Phase 2 Clinical Trial. Discover how Brepocitinib, an innovative JAK/TK inhibitor, is setting new standards in the treatment of non-infectious uveitis. 📈💊 Stay tuned for more updates as we bring you the latest in ophthalmic breakthroughs directly from Chicago! #AAO2024 #ClinicalTrials #Ophthalmology #InnovationInMedicine #ClinicianLink

See clearly with Dedicated IT at CSEP 2024 Regional Meeting for Ophthalmology! Explore how our simplified solutions are streamlining patient management to advanced diagnostics, we're lighting the way to a brighter future in ophthalmology. Don't blink or you'll miss out! #CSEP2024 #Ophthalmology #DedicatedIT #EyeCareInnovation

🔍 Discover the latest innovation in glaucoma treatment with the new Calibreye System! This breakthrough technology offers precise, minimally invasive solutions, ensuring better outcomes and enhanced patient care. Dive into the details and see how Calibreye is revolutionizing ophthalmology 👁. Read on this editorial by Sheybani Arsham, MD here: https://bit.ly/45UhB2O

𝐒𝐞𝐦𝐚𝐠𝐥𝐮𝐭𝐢𝐝𝐞 𝐚𝐧𝐝 𝐄𝐲𝐞 𝐇𝐞𝐚𝐥𝐭𝐡: 𝐒𝐨𝐫𝐭𝐢𝐧𝐠 𝐒𝐜𝐢𝐞𝐧𝐜𝐞 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐇𝐲𝐩𝐞 👁️💡 GLP-1 receptor agonists like Semaglutide are making waves—but let us not get carried away by the tide of catchy headlines! I have noticed some publications (JAMA Ophthalmology, I’m looking at you 👀) that seem also focused on clicks and attention. Sure, NAION sounds alarming, but it is still about as rare as finding a needle in a haystack. As always, we need to balance innovation with caution. For me, it’s about focusing on what truly matters—patient care—with a good dose of skepticism when the headlines start sounding too dramatic or euphoric. Find our comment: Klin Monbl Augenheilkd 2024;241(9):1021-1022. https://lnkd.in/eZ395scU How do you stay grounded amidst all the buzz? Would love to hear your thoughts! #Ophthalmology #Semaglutide #EyeHealth #ScientificBalance #InnovationAndSafety

Richard Adler, MD, FACS, shares important updates on the Phase 4 Switch trial presented at American Academy of Ophthalmology 2023. Learn more about the clinical significance of the Restasis and Cequa study with this video: https://bit.ly/3SztiHl #ManagedCare #DryEyeDisease

Breaking barriers in glaucoma treatment! Celanese Corporation and Glaukos Corporation join forces to introduce iDose(R) TR, a game-changer in sustained drug release for better patient outcomes. Discover how this innovative solution is reshaping ophthalmology! #GlaucomaInnovation #CelaneseImpact #MedicalAdvancements #EyeCare #TidbitThursday